BlackRock takes 5% stake in HLB amid FDA review
--------------------------------------------------------------------
Source: The Korea Herald
Published: 2026-03-04 16:14 UTC+10:00
Section: All News
Factuality Score: 100
Opinion Category: Neutral
Topics: Health, Culture & Entertainment, South Korea, Food & Agriculture, Drugs, World News
--------------------------------------------------------------------
Snippet:
BlackRock, the world’s largest asset manager, has become the second-largest shareholder of Korean biotechnology firm HLB, amid the US Food and Drug Administration's review of its liver cancer drug.
--------------------------------------------------------------------